![](https://ml-eu.globenewswire.com/media/b5f67881-a8fb-48db-ac8f-b56b53accc4b/small/kaerus-logo.png)
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being ...
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of neurodevelopment, today announced that it has initiated a Phase 1 …